- Title: Subtitle
- POSTER: ABCL-869: Rondecabtagene Autoleucel, a Dual-Targeting CD19/CD20 CAR T-Cell Product, Exhibits a Manageable Safety Profile With Low Rates of Grade≥3 CRS and ICANS in Relapsed/Refractory Large B-Cell Lymphoma
- Creators
- Sarah Larson - UCLA Medical CenterTahir Latif - Olive View-UCLA Medical CenterUmar Farooq - University of IowaLocke Bryan - Augusta UniversityStefan Ciurea - UC Irvine HealthNebu Koshy - Baylor Scott & White HealthBoyu Hu - Huntsman Cancer InstituteBradley Hunter - Intermountain HealthcareFelix Mensah - European Society for Blood and Marrow TransplantationMehdi Hamandani - Medical College of WisconsinHassaan Yasin - University of LouisvilleWilliam Clark - Virginia Commonwealth UniversityShashank Cingam - Louisiana State University Health Sciences Center ShreveportMatthew Fero - University of New MexicoSami Brake - Corewell HealthDave Shook - Lyell Immunopharma (United States)Akil Merchant - Cedars-Sinai Medical Center
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.26(Suppl 1), pp.S308-S308
- DOI
- 10.1016/S2152-2650(26)01123-7
- ISSN
- 2152-2650
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 08/2026
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9985222743002771
Abstract
POSTER: ABCL-869: Rondecabtagene Autoleucel, a Dual-Targeting CD19/CD20 CAR T-Cell Product, Exhibits a Manageable Safety Profile With Low Rates of Grade≥3 CRS and ICANS in Relapsed/Refractory Large B-Cell Lymphoma
Clinical lymphoma, myeloma and leukemia, Vol.26(Suppl 1), pp.S308-S308
08/2026
DOI: 10.1016/S2152-2650(26)01123-7
Details
Metrics
1 Record Views